Join ZEG Berlin at the 33rd International Conference on Pharmacoepidemiology and Clinical research in August, 2017. We will have oral and poster ... Read More
Are you collecting
the right core data?
To understand patient outcomes
we study real people
Primary data help to identify rare adverse outcomes and customize risk management plans. Our non-interventional studies can assist. Validated by treating physicians, we design studies to go to the source — real people.
Big data is not
We tailor pharmacoepidemiology studies
to your unique needs
Studies are more than demographics or geography. Our cohort studies collect targeted and potentially sensitive data not always available on electronic databases. Assessing real-use risks, we help to resolve safety concerns.
We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.
How do you navigate the changing landscape?
We keep your regulatory submission on track
Change is frequent in the regulatory environment. We are adept in adjusting across borders and differing requirements. Our project managers, with significant medical and epidemiology experience, develop and evaluate the study design and protocols, communicating with you at every step. The EURAS study design method is at the heart of our work.
ZEG’s methodology emerged from our study of ‘The Third Generation Pill Crisis’ of 1996-2002. Relieving international safety fears, the study found the increased incidence of deep vein thrombosis (DVT) was partly an artefact of inherent biases.
The EURAS-OC study, with our partners, was a turning point for ZEG, and its design has been used in many Post Authorization Safety Studies since.